FMP
NASDAQ
1.58 USD
0.04 (2.53%)
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
Healthcare
Biotechnology
https://www.candeltx.com
NASDAQ
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The c...
0001841387
US1374041093
137404109
117 Kendrick Street
617 916 5445
US
76
Jul 27, 2021
0001841387
NASDAQ
Biotechnology
Healthcare
137404109
US1374041093
US
1.58
0.96
84.44k
45.69M
-
0.66-1.95
1.47
-
-
-
-
-1.44
-
https://www.candeltx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.